In the BioHarmony Drug Report Database

"Preview" Icon

Azithromycin

Azasite, Azithromycin, Zithromax, Zmax (azithromycin) is a small molecule pharmaceutical. Azithromycin was first approved as Azasite on 1991-11-01. It is used to treat bacterial infections, chlamydia infections, haemophilus infections, infectious skin diseases, and mycoplasma pneumonia amongst others in the USA. It is known to target motilin receptor. Azithromycin’s patent is valid until 2024-02-14 (FDA).

 

Trade Name

 

Azasite, Azithromycin, Zithromax, Zmax
 

Common Name

 

azithromycin
 

ChEMBL ID

 

CHEMBL529
 

Indication

 

bacterial infections, chlamydia infections, haemophilus infections, infectious skin diseases, mycoplasma pneumonia, neisseriaceae infections, nontuberculous mycobacterium infections, otitis media, protozoan infections, staphylococcal infections, streptococcal infections, tonsillitis, urethritis
 

Drug Class

 

Antibiotics (Streptomyces strains)

Image (chem structure or protein)

Azithromycin structure rendering